Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
REGULATORY
Fukui Pref. Govt Launches On-Site Inspection at Kobayashi Kako over Itraconazole Contaminated with Sleep Inducer
The Fukui prefectural government carried out on December 9 an on-site inspection at Kobayashi Kako, in response to a Class I voluntary recall the company has issued for its oral antifungal agent itraconazole due to contamination with the sleep inducer…
To read the full story
Related Article
- Corporate Culture, Attitude of Management at Root of Kobayashi Kako Scandal: MHLW Official
January 5, 2021
- 2nd Death Reported for Tainted Itraconazole User, Doctor Says Causal Link Unlikely
December 18, 2020
- Kobayashi Kako Manually Managed Itraconazole Production; Hand-Written Record on Rilmazafone Mix-Up Found
December 17, 2020
- Kobayashi Kako Temporary Halts Shipments of All Products after Tainted Itraconazole Issue
December 15, 2020
- 1st Death Reported for Kobayashi Kako’s Tainted Itraconazole Product
December 14, 2020
- Kobayashi Kako Recalls Itraconazole over Hypnotic Contamination; Side Effects Confirmed
December 7, 2020
REGULATORY
- LDP Biosimilar Group Submits Request to Finance Minister, Seeks Continued Support
December 16, 2025
- LDP’s Patch League Urges Finance Minister to Continue Coverage, Support Prices
December 16, 2025
- Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests
December 15, 2025
- LDP Leans Towards “Special Charges” for OTC-Like Drugs, Not Coverage Removal
December 15, 2025
- Ishin Urges “Special Charge” Scheme for OTC-Like Drugs, Eyes FY2026 Launch
December 15, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…